Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.80 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.80 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.80 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.80 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.80 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.80 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.80 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711137 | 0.94 | CHRM2 (0.76) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL19129074 | 0.90 | TMEM97 (0.80) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL30107680 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL9047 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29359553 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL31023589 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695848 | 0.89 | CHRM2 (0.78) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8623049 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8170 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL6746375 | 0.89 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4656242-A2 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| WO-2005016196-A1 | COMPOSITIONS AND METHODS FOR DESTABILIZING LYSOSOMES TO INCREASE ONCOGENIC OR ABERRANT PROTEIN DEGRADATION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004050837-A2 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050842-A2 | ATM KINASE COMPOSITIONS AND METHODS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6417177-B1 | Chloroquine derivatives for the treatment of Parkinson's disease | ALPHA RESEARCH GROUP, LLC | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | CHRM2 4848/4885CHRM4 4804/4885CHRM5 4787/4885 |
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | CHRM2 4278/4885CHRM4 4731/4885CHRM5 4097/4885 |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | CHRM2 2268/4885CHRM4 3113/4885CHRM5 2993/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | CHRM2 4693/4885CHRM4 4785/4885CHRM5 4531/4885 |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | PRKCG, PRKAG2, PRKAG1 | CHRM2 3492/4885CHRM4 3944/4885CHRM5 3682/4885 |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MYOF, MTPN, TTN | CHRM2 3069/4885CHRM4 3565/4885CHRM5 3442/4885 |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, MYOF, MYH2 | CHRM2 2388/4885CHRM4 3970/4885CHRM5 4319/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | CHRM2 4789/4885CHRM4 4827/4885CHRM5 4815/4885 |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | CHRM2 3532/4885CHRM4 2569/4885CHRM5 1846/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | CHRM2 4834/4885CHRM4 4712/4885CHRM5 4740/4885 |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | UPF1, MYOF, MTPN | CHRM2 2998/4885CHRM4 2801/4885CHRM5 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.